---
title: "International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial"
nct_id: NCT02910609
overall_status: UNKNOWN
sponsor: Ankara University
study_type: OBSERVATIONAL
primary_condition: Patent Ductus Arteriosus
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02910609.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02910609"
ct_last_update_post_date: 2016-09-22
last_seen_at: "2026-05-12T06:36:35.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial

**Official Title:** International Experience in Timing And Choices of Treatment For Ductal Closure in Patent Ductus Arteriosus: INTERPDA Trial

**NCT ID:** [NCT02910609](https://clinicaltrials.gov/study/NCT02910609)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1000
- **Lead Sponsor:** Ankara University
- **Conditions:** Patent Ductus Arteriosus
- **Start Date:** 2017-01
- **Completion Date:** 2018-03
- **CT.gov Last Update:** 2016-09-22

## Brief Summary

The three options for the treatment of patent ductus arterioles (PDA) in preterm infants are conservative approach, pharmacological intervention and surgical ligation. There is not any randomized-controlled trial that demonstrates the superiority of these approaches in preterm infants.

## Detailed Description

Patent ductus arteriosus (PDA), of which incidence is inversely related to gestational age and birth weight, is one of the the most common conditions among preterm infants.

In recent years, the use of antenatal steroids, postnatal surfactant, noninvasive ventilation strategies and low oxygen saturation targets have affected the incidence of hemodynamically significant PDA (HSPDA). There is not any consensus about the best approach on the clinical management of PDA in preterm infants. Over past years, the management of HSPDA shifted to aggressive medical and surgical intervention from conservative treatment, but conservative treatment approach has been mainly concerned again nowadays.

Today, the three options for the treatment of PDA in preterm infants are conservative approach, pharmacological intervention and surgical ligation. There is not any randomized-controlled trial that demonstrates the superiority of these approaches in preterm infants. Many countries including developed countries only give recommendations, instead of publishing guidelines, on screening, timing of treatment and treatment choices of PDA, because of the differences on management of PDA between the centers even within a single center.

Timing of PDA treatment and treatment choices at preterm infants born before 28 gestation weeks' differ in our country also in many countries over the world. In this study, it is aimed to record the managements of PDA detected beyond postnatal 3 days, to compare the effects of the managements at postnatal 3-7 days and after 7 days on closure, surgical ligation rates and side effects of drugs.

## Eligibility

- **Minimum age:** 1 Day
- **Maximum age:** 28 Days
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Infants born at 24 0/7-28 6/7 gestation weeks'
* PDA detected with ductal diameter equal or greater than 1.5 mm and LA/Ao equal or greater than 1.5 on echocardiography at or after postnatal 72 hours of life

Exclusion Criteria:

* Infants died before 72 hours of life
* Infants detected PDA but treated before 72 hours of life
```

## Arms

- **Management at PN 3-7 days** — Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
- **Management after PN 7 days** — Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life

## Interventions

- **Echocardiography** (DEVICE) — Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.

## Primary Outcomes

- **Spontan closure rate** _(time frame: 3 months)_ — Rate of patients with spontaneous ductal closure

## Secondary Outcomes

- **Surgical ligation rate** _(time frame: 3 months)_
- **Complications of prematurity** _(time frame: 3 months)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02910609.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02910609*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*